ANIP Ani Pharmaceuticals Inc
Price (delayed)
$62.53
Market cap
$1.32B
P/E Ratio
52.99
Dividend/share
N/A
EPS
$1.18
Enterprise value
$1.36B
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers),
Highlights
Ani Pharmaceuticals's revenue has increased by 34% YoY and by 4.2% from the previous quarter
The gross profit has grown by 31% year-on-year
The company's EPS fell by 27% QoQ
Ani Pharmaceuticals's net income has decreased by 24% QoQ
Key stats
What are the main financial stats of ANIP
Market
Valuations
Earnings
Shares outstanding
21.04M
Market cap
$1.32B
Enterprise value
$1.36B
Price to earnings (P/E)
52.99
Price to book (P/B)
2.88
Price to sales (P/S)
2.24
EV/EBIT
23.91
EV/EBITDA
11.47
EV/Sales
2.52
Revenue
$538.95M
EBIT
$56.91M
EBITDA
$118.65M
Free cash flow
$113.06M
Per share
Balance sheet
Liquidity
EPS
$1.18
Free cash flow per share
$5.85
Book value per share
$21.73
Revenue per share
$27.89
TBVPS
$36.72
Total assets
$920.75M
Total liabilities
$440.14M
Debt
$285.24M
Equity
$455.76M
Working capital
$415.48M
Debt to equity
0.63
Current ratio
3.97
Quick ratio
2.95
Net debt/EBITDA
0.38
Margins
Efficiency
Dividend
EBITDA margin
22%
Gross margin
61.3%
Net margin
5%
Operating margin
9.3%
Return on assets
2.8%
Return on equity
5.7%
Return on invested capital
9.4%
Return on capital employed
7.3%
Return on sales
10.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIP stock price
How has the Ani Pharmaceuticals stock price performed over time
Intraday
4.11%
1 week
15.11%
1 month
4.18%
1 year
1.79%
YTD
13.4%
QTD
-1.81%
Financial performance
How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$538.95M
Gross profit
$330.58M
Operating income
$49.96M
Net income
$27.02M
Gross margin
61.3%
Net margin
5%
The company's operating income has surged by 98% YoY but it fell by 14% QoQ
ANIP's operating margin is up by 48% year-on-year but it is down by 17% since the previous quarter
Ani Pharmaceuticals's revenue has increased by 34% YoY and by 4.2% from the previous quarter
The gross profit has grown by 31% year-on-year
Growth
What is Ani Pharmaceuticals's growth rate over time
Valuation
What is Ani Pharmaceuticals stock price valuation
P/E
52.99
P/B
2.88
P/S
2.24
EV/EBIT
23.91
EV/EBITDA
11.47
EV/Sales
2.52
The company's EPS fell by 27% QoQ
ANIP's P/E is 25% below its last 4 quarters average of 67.6
The P/B is 15% above the 5-year quarterly average of 2.4 but 4.8% below the last 4 quarters average of 2.9
The company's equity rose by 11% YoY
Ani Pharmaceuticals's revenue has increased by 34% YoY and by 4.2% from the previous quarter
The price to sales (P/S) is 10% lower than the last 4 quarters average of 2.4 and 7% lower than the 5-year quarterly average of 2.3
Efficiency
How efficient is Ani Pharmaceuticals business performance
Ani Pharmaceuticals's ROIC has soared by 194% YoY but it has decreased by 16% from the previous quarter
The company's return on sales has surged by 126% YoY but it fell by 18% QoQ
The return on equity has declined by 28% since the previous quarter
The ROA has contracted by 26% from the previous quarter
Dividends
What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIP.
Financial health
How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 109% more than its total liabilities
ANIP's quick ratio is up by 8% year-on-year
Ani Pharmaceuticals's total assets has increased by 7% YoY
The debt is 37% lower than the equity
The company's equity rose by 11% YoY
The debt to equity has decreased by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.